Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huang'e Capsule (黄莪胶囊), marketed under the brand name Jin Qianliekang (金前列康), is a traditional Chinese medicine (TCM) developed by Zhejiang Conba Pharmaceutical. It is a multi-herb formulation containing Astragalus, peach kernel, Curcuma, rhubarb, and several other botanical ingredients. The drug is approved in China (approval number Z20110006) for the treatment of stage I and II benign prostatic hyperplasia (BPH) and chronic prostatitis, particularly for patients presenting with qi deficiency, blood stasis, and damp-heat obstruction. Its therapeutic mechanism involves tonifying qi, improving blood circulation, and clearing damp-heat, which correlates with a reduction in inflammatory markers such as interleukin-8 (IL-8).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on huang'e capsule.